Acute and chronic cognitive effects of levodopa and dopamine agonists on patients with Parkinson's disease: A review

Therapeutic Advances in Psychopharmacology

Volumn 3, Issue 2, 2013, Pages 101-113

  Poletti, Michele ^a   Bonuccelli, Ubaldo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

acute cognitive effect; chronic cognitive effect; cognition; dopamine agonists; executive functions; levodopa; Parkinson's disease

Indexed keywords

APOMORPHINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PERGOLIDE; PRAMIPEXOLE;

BRADYKINESIA; CLINICAL FEATURE; COGNITION; CORPUS STRIATUM; DISEASE DURATION; DISEASE SEVERITY; DOPAMINE BLOOD LEVEL; DOPAMINERGIC ACTIVITY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DYSKINESIA; EPISODIC MEMORY; EXECUTIVE FUNCTION; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLOBUS PALLIDUS; HUMAN; IMPULSE CONTROL DISORDER; LEARNING; MENTAL STRESS; MILD COGNITIVE IMPAIRMENT; NERVE STIMULATION; NEUROANATOMY; NEUROCHEMISTRY; NEUROPATHOLOGY; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PREFRONTAL CORTEX; PRESCRIPTION; PRIORITY JOURNAL; REACTION TIME; REINFORCEMENT; REVIEW; RISK FACTOR; SEMANTICS; SYSTEMATIC REVIEW; THALAMUS; VISUAL MEMORY;

EID: 84997901801     PISSN: 20451253     EISSN: 20451261     Source Type: Journal    
DOI: 10.1177/2045125312470130     Document Type: Review

References (90)

1. Aarsland D. Anderson K. Larsen J. Lolk A. Kragh-Sorensen P. (2003) Prevalence and characteristics of dementia in Parkinson disease. A 8 year prospective study. Arch Neurol 60: 387–392.
2. Alexander G. Delong M. Strick P. (1986) Parallel organisation of functionally segregated circuits linking basal ganglia and cortex. Ann Rev Neurosci 9: 357–381.
3. Anqwin A. Arnott W. Copland D. Haire M. Murdoch B. Silburn P. et al. (2009) Semantic activation in Parkinson's disease patients on and off levodopa. Cortex 45: 950–959.
4. Baloyannis S. Costa V. Baloyannis I. (2006) Morphological alterations of the synapses in the locus ceruleus in Parkinson's disease. J Neurol Sci 248: 35–41.
5. Beato R. Levy R. Pillon B. du Montcel S. Deweer B. Bonnet A. et al. (2008) Working memory in Parkinson's disease patients: clinical features and response to levodopa. Arq Neuropsyquiatr 66: 147–151.
6. Benoit M. Robert P. (2011) Imaging correlates of apathy and depression in Parkinson's disease. J Neurol Sci 310: 58–60.
7. Bohnen N. Kaufer D. Hendrickson R. Ivanco L. Lopresti B. Costantine G. et al. (2006) Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementias. J Neurol 253: 242–247.
8. Bonelli R. Cummings J. (2007) Frontal-subcortical circuitry and behavior. Dialogues Clin Neurosci 9: 141–151.
9. Bonuccelli U. Del Dotto P. Rascol O. (2009) Role of dopamine receptor agonists in the treatment of early Parkinson's disease. Parkinsonism Relat Disord 15: S44–S53.
10. Bonuccelli U. Pavese N. (2006) Dopamine agonists in the treatment of Parkinson's disease. Expert Rev Neurother 6: 81–89.
11. Braak H. Del Tredici K. Rub U. de Vos R. Jansen Steur E. Braak E. (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24: 197–211.
12. Brusa L. Bassi A. Stefani A. Pierantozzi M. Peppe A. Caramia M. et al. (2003) Pramipexole in comparison to l-dopa: a neuropsychological study. J Neural Transm 110: 373–380.
13. Brusa L. Tiraboschi P. Koch G. Peppe A. Pierantozzi M. Ruggieri S. et al. (2005) Pergolide effect on cognitive functions in early mild Parkinson's disease. J Neural Transm 112: 231–237.
14. Calabresi P. Picconi B. Parnetti L. Di Filippo M. (2006) A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance. Lancet Neurol 5: 974–983.
15. Chaudhury K. Healy D. Schapira A. (2006) Non motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 5: 235–245.
16. Chudasama Y. Robbins T. (2006) Functions of frontostriatal systems in cognition: comparative neuropsychopharmacological studies in rats, monkeys and humans. Biol Psychol 73: 19–38.
17. Cools R. (2006) Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease. Neurosci Biobehav Rev 30: 1–23.
18. Cools R. Altamirano L. D’Esposito M. (2006) Reversal learning in Parkinson's disease depends of medication status and outcome valence. Neuropsychologia 44: 1663–1673.
19. Cools R. Barker R. Sahakian B. Robbins T. (2001) Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cereb Cortex 11: 1136–1143.
20. Cools R. Barker R. Sahakian B. Robbins T. (2003) L-dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease. Neuropsychologia 41: 1431–1441.
21. Cools R. Clark L. Owen A. Robbins T. (2002a) Defining the neural mechanism of probabilistic reversal learning using event-related functional magnetic resonance imaging. J Neurosci 22: 4583–4587.
22. Cools R. Lewis S. Clark L. Barker R. Robbins T. (2007) L-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson's disease. Neuropsychopharmachology 32: 180–189.
23. Cools R. Myakawa A. Sheridan M. D’Esposito M. (2010) Enhanced frontal function in Parkinson's disease. Brain 133: 225–233.
24. Cools R. Stefanova E. Barker R. Robbins T. Owen A. (2002b) Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET. Brain 125: 584–594.
25. Costa A. Peppe A. Brusa L. Caltagirone C. Gatto I. Carlesimo G. (2008) Levodopa improves time-based prospective memory in Parkinson's disease. J Int Neuropsychol Soc 14: 601–610.
26. Costa A. Peppe A. Dell’Agnello G. Caltagirone C. Carlesimo G. (2009) Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory. Neuropsychologia 47: 1374–1381.
27. Costa A. Peppe A. Dell’Agnello G. Carlesimo G. Murri L. Bonuccelli U. et al. (2003) Dopaminergic modulation of visuospatial working memory in Parkinson's disease. Dementia Geriatr Cogn Disord 15: 55–66.
28. Deleu D. Northway M.G. Hanssens Y. (2002) Clinical pharmacokinetic and pharma-codynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet 41: 261–309.
29. Domellof M. Elgh E. Forsgren L. (2011) The relation between cognition and motor dysfunction in drug-naïve newly diagnosed patients with Parkinson's disease. Mov Disord 26: 2183–2189.
30. Drijgers R. Verhey F. Tissingh G. van Domburg P. Aalten P. Leentjens A. (2012) The role of the dopaminergic system in mood, motivation and cognition in Parkinson's disease: a double-blind randomized placebo-controlled experimental challenge with pramipexole and methylphenidate. J Neurol Sci 320: 121–126.
31. Edelstyn N. Shepherd T. Mayes A. Sherman S. Ellis S. (2010) Effect of disease severity and dopaminergic medication on recollection and familiarity in patients with idiopathic nondementing Parkinson's. Neuropsychologia 48: 1367–1375.
32. Elmer L. Schwid S. Eberly S. Goetz C. Fahn S. Kieburtz K. et al. (2006) Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms. J Neurol Sci 248: 78–83.
33. Fera F. Nicoletti G. Cerasa A. Romeo N. Gallo O. Gioia M. et al. (2007) Dopaminergic modulation of cognitive interference after pharmacological washout in Parkinson's disease. Brain Res Bull 74: 75–83.
34. Foerde K. Shohamy D. (2011) Feedback timing modulates brain systems for learning in humans. J Neurosci 31: 13157–13166.
35. Frank M. (2006) Hold your horses: a dynamic neurocomputational role of the subthalamic nucleus in decision making. Neur Netw 19: 1120–1136.
36. Frank M. Samanta J. Moustafa A. Sherman S. (2007) Hold your horses: impulsivity, deep brain stimulation and medication in parkinsonism. Science 318: 1309–1312.
37. Frank M. Seeberger L. O’Reilly R. (2004) By carrot or by stick: cognitive reinforcement learning in parkinsonism. Science 306: 1940–1943.
38. Gotham A. Brown R. Marsden C. (1986) Levodopa treatment may benefit or impair frontal function in Parkinson's disease. Lancet 2: 970–971.
39. Gotham A. Brown R. Marsden C.D. (1988) Frontal cognitive function in patients with Parkinson's disease ‘on’ and ‘off’ levodopa. Brain 111: 299–321.
40. Goto Y. Grace A. (2005) Dopaminergic modulation of limbic and cortical drive of nucleus accumbens in goal-directed behaviour. Nat Neurosci 8: 805–812.
41. Grace A. (2000) The tonic/phasic model of dopamine system regulation and its implications for understanding alcohol and psychostimulant craving. Addiction 95(Suppl. 2): S119–S128.
42. Guttman M. Boileau I. Warsh J. Saint-Cyr J. Ginovart N. McCluskey T. et al. (2007) Brain serotonin transporter binding in nondepressed patients with Parkinson's disease. Eur J Neurol 14: 523–528.
43. Hanagasi H. Gurvit H. Unsalan P. Horozoglu H. Tuncer M. Feyzioglu A. et al. (2011) The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study. Mov Disord 26: 1851–1858.
44. Hanna-Pladdy B. Heilman K. (2010) Dopaminergic modulation of the planning phase of skill acquisition in Parkinson's disease. Neurocase 16: 182–190.
45. Hernandez-Lopez S. Tkatch T. Perez-Garci E. Galarraga E. Bargas J. Hamm H. et al. (2000) D2 dopamine receptors in striatal medium spiny neurons reduce L-type Ca2+ currents and excitability via a novel PLC (Beta)1-IP3 calcineurin signalling cascade. J Neurosci 20: 8987–8995.
46. Hornykiewicz O. (1974) The mechanism of action of l-dopa in Parkinson's disease. Life Sci 15: 1249–1259.
47. Hosokai Y. Nishio Y. Hirayama K. Takeda A. Ishioka T. Sawada Y. et al. (2009) Distinct patterns of cerebral glucose metabolism in Parkinson's disease with and without mild cognitive impairment. Mov Disord 23: 854–862.
48. Hughes A. Daniel S. Kilford L. Lees A. (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 155: 181–184.
49. Jahanshahi M. Wilkinson L. Gahir H. Dharmarinda A. Lagnado D. (2010) Medication impairs probabilistic classification learning in Parkinson's disease. Neuropsychologia 48: 1096–1103.
50. Jenner P. Langston J. (2011) Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline. Mov Disord 26: 2316–2323.
51. Kish S. Shannak K. Hornykiewicz O. (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 318: 876–880.
52. Kostic V. Filippi M. (2011) Neuroanatomical correlates of depression and apathy in Parkinson's disease: magnetic resonance imaging studies. J Neurol Sci 310: 61–63.
53. Kulisevsky J. Avila A. Barbanoj M. Antonijan R. Berthier M. Gironell A. (1996) Acute effects of levodopa on neuropsychological performance in stable and fluctuating Parkinson's disease patients at different levodopa plasma levels. Brain 119: 2121–2132.
54. Kulisevsky J. Garcia-Sanchez C. Berthier M. Barbanoj M. Pascual-Sedano B. Gironell A. et al. (2000) Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients. Mov Disord 15: 613–626.
55. Lyoo Ch. Jeong Y. Ryu Y. Rinne J. Lee M. (2010) Cerebral glucose metabolism of Parkinson's disease patients with mild cognitive impairment. Eur J Neurol 64: 65–73.
56. MacDonald P. MacDonald A. Seergobin K. Tamjeedi R. Ganjavi H. Provost J. et al. (2011) The effect of dopamine therapy on ventral and dorsal striatum-mediated cognition in Parkinson's disease: support from functional fMRI. Brain 134: 1447–1463.
57. Marsh L. Biglan K. Gerstenhaber M. Williams J. (2009) Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study. Mov Disord 24: 277–287
58. Martin M. Kliegel M. McDaniel M. (2003) The involvement of executive functions in prospective memory performance of adults. Int J Psychol 38: 195–206.
59. Maruyama W. Naoi M. Narabayashi H. (1996) The metabolism of L-Dopa and L-threo-3, 4-dihydroxyphreylserine and their effects on monoamines in the human brain: analysis of the intraventricular fluid from parkinsonian patients. J Neurol Sci 139: 141–148.
60. Mattis P. Tang C. Ma Y. Eidelberg D. (2011) Networks correlates of the cognitive response to levodopa in Parkinson disease. Neurology 77: 858–865.
61. Miyake A. Friedman N. (2012) The nature and organization of individual differences in executive functions: four general conclusions. Curr Dir Psychol Sci 21: 8–14.
62. Mollion H. Ventre-Dominey J. Dominey P. Broussolle E. (2003) Dissociable effects of dopaminergic therapy on spatial versus non-spatial working memory in Parkinson's disease. Neuropsychologia 41: 1442–1451.
63. Molloy S. Rowan E. O’Brien J. McKeith I. Wesnes K. Burn D. (2006) Effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 77: 1323–1328.
64. Morcom A. Bullmore E. Huppert F. Lennox B. Praseedom A. Linnington H. et al. (2010) Memory encoding and dopamine in the aging brain: a psychopharmacological neuroimaging study. Cereb Cortex 20: 743–757.
65. Muller T. Benz S. Przuntek H. (2002) Apomorphine delays simple reaction times in Parkinsonian patients. Parkinsonism Relat Disord 8: 357–360.
66. Muslimovic D. Post B. Speelman J. Schmand B. (2005) Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 65: 1239–1245.
67. Nobili F. Arnaldi D. Campus C. Ferrara M. De Carli F. Brugnolo A. et al. (2011) Brain perfusion correlates of cognitive and nigrostriatal functions in de novo Parkinson's disease. Eur J Nucl Med Mol Imaging 38: 2209–2218.
68. Owen A. (2004) Cognitive dysfunction in Parkinson's disease: the role of frontostriatal circuitry. Neuroscientist 10: 525–537.
69. Pappatà S. Santangelo G. Aarsland D. Vicidomini C. Longo K. Bronnick K. et al. (2011) Mild cognitive impairment in drug-naïve patients with PD is associated with cerebral hypometabolism. Neurology 77: 1357–1362.
70. Pascual-Sedano B. Kulisevsky J. Barbanoj M. Garcia-Sanchez C. Campolongo A. Gironell A. et al. (2008) Levodopa and executive performance in Parkinson's disease: a randomized study. J Int Neuropsychol Soc 14: 832–841.
71. Perachon S. Schwartz J. Sokoloff P. (1999) Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors. Eur J Pharmacol 366: 293–300.
72. Poewe W. Antonini A. Zijlmans J. Burkhard P. Vingerhoets F. (2010) Levodopa in the treatment of Parkinson's disease: an old drug still going strong. Clin Interv Aging 7: 229–238.
73. Poletti M. Bonuccelli U. (2012) Orbital and ventromedial prefrontal cortex functioning in Parkinson's disease: Neuropsychological evidence. Brain Cogn 79: 23–33.
74. Poletti M. De Rosa A. Bonuccelli U. (2012a) Affective symptoms and cognitive functions in Parkinson's disease. J Neurol Sci 317: 97–102.
75. Poletti M. Frosini D. Lucetti D. Del Dotto P. Ceravolo R. Bonuccelli U. (2010) Decision making in de novo Parkinson's disease. Mov Disord 25: 1432–1436.
76. Poletti M. Frosini D. Pagni C. Baldacci F. Nicoletti V. Tognoni G. et al. (2012b) Mild cognitive impairment and cognitive-motor relationships in newly diagnosed drug-naïve patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 83: 601–606.
77. Rektorova I. Rektor I. Bares M. Dostal V. Ehler E. Fanrdlova Z. et al. (2005) Cognitive performance in people with Parkinson's disease and mild and moderate depression: effects of dopamine agonists in add-on to L-dopa therapy. Eur J Neurol 12: 9–15.
78. Relja M. Klepac N. (2006) A dopamine agonist, pramipexole, and cognitive functions in Parkinson's disease. J Neurol Sci 248: 251–254.
79. Rowe J. Hughes L. Ghosh B. Eckstein D. Williams-Gray C. Fallon S. et al. (2008) Parkinson's disease and dopaminergic therapy: differential effects on movement, reward and cognition. Brain 131: 2094–2105.
80. Santangelo G. Trojano L. Vitale C. Ianniciello M. Amboni M. Grossi D. et al. (2007) A neuropsychological longitudinal study in Parkinson's disease patients with and without hallucinations. Mov Disord 22: 2418–2425.
81. Sawamoto N. Piccini P. Hotton G. Pavese N. Thielemans K. Brooks D. (2008) Cognitive deficits and striato-frontal dopamine release in Parkinson's disease. Brain 131: 1294–1302.
82. Scholtissen B. Verhey F. Adam J. Weber W. Leentjens A. (2006) Challenging the serotoninergic system in Parkinson disease patients: effects of cognition, mood and motor performance. Clin Neuropharmacol 29: 276–285.
83. Schrag A. Jahanshahi M. Quinn N. (2000) How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 15: 1112–1118.
84. Shohamy D. Adcock R. (2010) Dopamine and adaptive memory. Trend Cogn Sci 14: 464–472.
85. Starkstein S. Merello M. Jorge R. Brockman S. Bruce D. Power B. (2009) The syndromal validity and nosological position of apathy in Parkinson's disease. Mov Disord 24: 1211–1216.
86. Takahashi H. Yamada M. Suhara T. (2012) Functional significance of central D1 receptors in cognition: beyond working memory. J Cereb Blood Flow Metab 32: 1248–1258.
87. Vanderploeg R. Schinka J. Retzlaff P. (1994) Relationships between measures of auditory verbal learning and executive functioning. J Clin Exp Neuropsychol 16: 243–252.
88. Vingerhoerts F. Schulzer M. Calne D. Snow B. (1997) Which clinical sign of Parkinson's disease reflects the nigrostriatal lesion? Ann Neurol 41: 58–64.
89. Weintraub D. Koester J. Potenza M. Siderowf A. Stacy M. Voon V. et al. (2010) Impulse control disorders in Parkinson's disease: a cross-sectional study of 3090 patients. Arch Neurol 67: 589–595.
90. Yeterian E. Pandya D. (1991) Prefrontostriatal connections in relation to cortical architectonic organisation in rhesus monkeys. J Comp Neurol 312: 43–67.